These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 798191)

  • 1. Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics.
    Tanghe A; Declercq H
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):50-3. PubMed ID: 798191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
    Pacquay M; Brasseur F
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre study on the efficacy and safety of individualized dosage of haloperidol (Haldol) in refractory chronic psychotics.
    Nicodeme A; Vranckx-Haenen J; Wouters J
    Acta Psychiatr Belg; 1977; 77(4):516-29. PubMed ID: 337756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of Haldol at high doses in chronic schizophrenia].
    Paquay J; Brasseur F
    Acta Psychiatr Belg; 1976 May; 76(3):491-504. PubMed ID: 1020684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with bromperidol in chronic psychoses].
    Bellomo LE; Rosset N; Tellarini L; Forconesi N
    Acta Psiquiatr Psicol Am Lat; 1988 Sep; 34(3):230-6. PubMed ID: 3071092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
    Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
    Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of outpatients with high doses of haloperidol].
    Shopsin B; Kline N
    Acta Psiquiatr Psicol Am Lat; 1981 Jul; 27(3):236-42. PubMed ID: 7348083
    [No Abstract]   [Full Text] [Related]  

  • 12. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open study with bromperidol in hospitalized chronic schizophrenic patients.
    Hermans W
    Acta Psychiatr Belg; 1978; 78(1):89-95. PubMed ID: 347883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic treatment of schizophrenia with injectable bromperidol decanoate].
    Suárez Richards M
    Acta Psiquiatr Psicol Am Lat; 1985 Sep; 31(3):222-8. PubMed ID: 2870608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB
    J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
    Moleman P; Schmitz PJ; Ladee GA
    J Clin Psychiatry; 1982 Dec; 43(12):492-6. PubMed ID: 7161250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of haloperidol by -methyldopa in the treatment of schizophrenic patients.
    Chouinard G; Serrano PM; Tetreault L
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):473-83. PubMed ID: 4198310
    [No Abstract]   [Full Text] [Related]  

  • 18. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
    Leff JP; Tress KH
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of haloperidol in chronic psychotic patients.
    Lapolla A
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl l:68-77. PubMed ID: 6051725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.